OOIR: Observatory of International Research

Papers

(The H4-Index of Diabetes Obesity & Metabolism is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside	416
Disparity in the rural‐urban distribution of clinical trial sites used in studies cited by diabetes treatment guidelines	208
	138
Association between stress hyperglycaemia and in‐hospital cardiac events after coronary artery bypass grafting in patients without diabetes: A retrospective observational study of 5450 patients	117
	112
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study	112
Diabetes, Obesity and Metabolism	93
	89
A meta‐analysis of the association between RBP4 rs3758539 genotype and metabolic syndrome factors	86
Body mass index and remote ischaemic conditioning efficacy in acute ischaemic stroke patients: A post hoc analysis of the Remote Ischaemic Conditioning for Acute Moderate Ischaemic Stroke (RICAMIS) tr	86
Obesity‐associated metabolites in relation to type 2 diabetes risk: A prospective nested case‐control study of the CARRS cohort	78
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial	75
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump	71
Assessment of circulating insulin using liquid chromatography‐mass spectrometry during insulin glargine treatment in type 2 diabetes: Implications for estimating insulin sensitivity and β‐cell functio	69
Surfing the waves of the COVID‐19 pandemic with diabetes mellitus: Analysis of changes in the diabetes therapy, metabolism and physical activity of 92 992 people living with type 1 or type	67
Reduction of clinically important low glucose excursions with a long‐term implantable continuous glucose monitoring system in adults with type 1 diabetes prone to hypoglycaemia: the France Adoption Ra	66
Mediators of the effects of canagliflozin on N‐terminal pro‐brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial	66
Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon‐like peptide‐1 receptor agonists	65
Interactions between age, sex and visceral adipose tissue on brain ageing	64
Regional socioeconomic deprivation associated with the use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in adults with type 2 diabetes in Germany	63
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial	62
Associations of body mass index, waist circumference and the weight‐adjusted waist index with daily living ability impairment in older Chinese people: A cross‐sectional study of the Chinese Longitudin	62
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity	62
Types of diabetes during pregnancy and risk of depression and anxiety in offspring from childhood to young adulthood	61
Pushing the limits of insulin delivery 100 years later: A case study of a race across Canada	61

Short‐term efficacy and safety of metformin in individuals with type 2 diabetes and mild hepatic impairment: A propensity score‐matched real‐world study	59
High‐protein vegan and omnivorous diets improve peripheral insulin sensitivity to a similar extent in people with type 2 diabetes	58
The predictive value of estimated glucose disposal rate and its association with myocardial infarction, heart failure, atrial fibrillation and ischemic stroke	57
Sustained weight reduction following 12 weeks of intermittent fasting intervention in people with insulin‐treated type 2 diabetes—Two‐year follow‐up of the randomised controlled InterFast‐2	56
Correction to “Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP	53
Chemerin loss‐of‐function attenuates glucagon‐like peptide‐1 secretion in exercised obese mice	51
Glucagon‐like peptide‐1 analogues reduce alcohol intake	51
Diabetes, Obesity and Metabolism	51
Most hospitalised patients with type 2 diabetes benefit from continuous glucose monitoring compared to point‐of‐care glucose testing in a non‐intensive care unit setting: A heterogeneity of treatment	48
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (	47
Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study	47
Glucose control using fast‐acting insulin aspart in a real‐world setting: A 1‐year, two‐centre study in people with type 1 diabetes using continuous glucose monitoring	46
Issue Information	45
Combining polygenic risk scores and human leukocyte antigen variants for personalized risk assessment of type 1 diabetes in the Taiwanese population	42
Glycaemic control and sepsis risk in adults with type 1 diabetes	42
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries	42
	41
Back Cover	41